Guidelines

New guidelines address primary cutaneous T-cell lymphoproliferative disorders

Publish date: April 14, 2014

 

AT THE NCCN ANNUAL CONFERENCE

Dr. Zelenetz is a scientific adviser for Cancer Genetics Inc. and Gilead and has received consulting fees, honoraria, and/or grant or other research support from Celgene Corp., Cephalon Inc., Genentech Inc., GlaxoSmithKline, Roche Laboratories Inc., sanofi-aventis U.S., and Seattle Genetics Inc.

Pages

Recommended Reading

VIDEO: The DecisionDx-Melanoma test can predict metastasis of sentinel node-negative melanomas
MDedge Hematology and Oncology
In situ melanoma high risk for subsequent diagnosis
MDedge Hematology and Oncology
Cell-penetrating domain improves therapeutic cancer vaccine potency
MDedge Hematology and Oncology
Melanomas were less invasive at diagnosis in patients with established dermatologist
MDedge Hematology and Oncology
Delayed response in ipilimumab therapy
MDedge Hematology and Oncology
Immunotherapy for melanoma progresses with some interesting response patterns
MDedge Hematology and Oncology
New study supports imiquimod for lentigo maligna
MDedge Hematology and Oncology
Substantial delay seen in melanoma surgery for Medicare patients
MDedge Hematology and Oncology
Patients with PD-L1–positive tumors had better response to immune checkpoint inhibitor
MDedge Hematology and Oncology
Monoclonal antibody pinpoints BRAF status in melanoma
MDedge Hematology and Oncology